Cover Image
市場調查報告書

ImmunoVaccine Technologies Inc. - 產品平台分析

Immunovaccine, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 192653
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
ImmunoVaccine Technologies Inc. - 產品平台分析 Immunovaccine, Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月13日 內容資訊: 英文 40 Pages
簡介

ImmunoVaccine Technologies Inc. 是總公司設在加拿大的生物科技企業,進行癌症治療用及感染疾病、家畜用疫苗的開發與銷售。 該公司的產品DPX-0907是辨識癌症細胞並攻擊的活化免疫系統的疫苗。

本報告提供ImmunoVaccine Technologies Inc. 的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

ImmunoVaccine Technologies Inc. 的基本資料

  • ImmunoVaccine Technologies Inc. 概要
  • 主要資訊
  • 企業資料

ImmunoVaccine Technologies Inc. :R&D概要

  • 主要的治療範圍

ImmunoVaccine Technologies Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

ImmunoVaccine Technologies Inc. :開發中產品概況

  • 在臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

ImmunoVaccine Technologies Inc. :藥物簡介

  • DPX-0907
  • DPX-Survivac
  • DPX-RSV
  • Vaccine for Cocaine Addiction
  • DPX-Ebola
  • hepatitis B vaccine
  • influenza strain H5N1 vaccine
  • malaria vaccine
  • pertussis (acellular) vaccine
  • dengue vaccine
  • herpes simplex virus type 2 vaccine
  • marburg vaccine
  • tuberculosis vaccine

ImmunoVaccine Technologies Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ImmunoVaccine Technologies Inc. :最新的開發平台資訊

ImmunoVaccine Technologies Inc. :開發暫停中的計劃

ImmunoVaccine Technologies Inc. :開發中止的產品

  • 開發中止的產品簡介

ImmunoVaccine Technologies Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08086CDB

Summary

Global Markets Direct's, 'Immunovaccine, Inc. - Product Pipeline Review - 2016', provides an overview of the Immunovaccine, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunovaccine, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Immunovaccine, Inc.
  • The report provides overview of Immunovaccine, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Immunovaccine, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Immunovaccine, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Immunovaccine, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Immunovaccine, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Immunovaccine, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immunovaccine, Inc. Snapshot
    • Immunovaccine, Inc. Overview
    • Key Information
    • Key Facts
  • Immunovaccine, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Immunovaccine, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Immunovaccine, Inc. - Pipeline Products Glance
    • Immunovaccine, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immunovaccine, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Immunovaccine, Inc. - Drug Profiles
    • DPX-Survivac
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPX-RSV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cocaine Addiction
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPX-Ebola
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPXE-7
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • malaria vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Zika virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immunovaccine, Inc. - Pipeline Analysis
  • Immunovaccine, Inc. - Pipeline Products by Target
  • Immunovaccine, Inc. - Pipeline Products by Route of Administration
  • Immunovaccine, Inc. - Pipeline Products by Molecule Type
  • Immunovaccine, Inc. - Recent Pipeline Updates
  • Immunovaccine, Inc. - Dormant Projects
  • Immunovaccine, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Pseudomonas vaccine
  • Immunovaccine, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immunovaccine, Inc., Key Information
  • Immunovaccine, Inc., Key Facts
  • Immunovaccine, Inc. - Pipeline by Indication, 2016
  • Immunovaccine, Inc. - Pipeline by Stage of Development, 2016
  • Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2016
  • Immunovaccine, Inc. - Partnered Products in Pipeline, 2016
  • Immunovaccine, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Immunovaccine, Inc. - Out-Licensed Products in Pipeline, 2016
  • Immunovaccine, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Immunovaccine, Inc. - Phase II, 2016
  • Immunovaccine, Inc. - Phase I, 2016
  • Immunovaccine, Inc. - Preclinical, 2016
  • Immunovaccine, Inc. - Pipeline by Target, 2016
  • Immunovaccine, Inc. - Pipeline by Route of Administration, 2016
  • Immunovaccine, Inc. - Pipeline by Molecule Type, 2016
  • Immunovaccine, Inc. - Recent Pipeline Updates, 2016
  • Immunovaccine, Inc. - Dormant Developmental Projects,2016
  • Immunovaccine, Inc. - Discontinued Pipeline Products, 2016

List of Figures

  • Immunovaccine, Inc. - Pipeline by Top 10 Indication, 2016
  • Immunovaccine, Inc. - Pipeline by Stage of Development, 2016
  • Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2016
  • Immunovaccine, Inc. - Partnered Products in Pipeline, 2016
  • Immunovaccine, Inc. - Pipeline by Target, 2016
  • Immunovaccine, Inc. - Pipeline by Route of Administration, 2016
  • Immunovaccine, Inc. - Pipeline by Molecule Type, 2016
Back to Top